Market Research Logo

Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021

Global Hospital-acquired Pneumonia (HAP) Drugs Market 2017-2021

About Hospital Acquired Pneumonia (HAP) Drugs

HAP is a type of pneumonia that is caused after 48 hours of hospitalization. HAP is one of the major challenges faced by the public healthcare system today. The disease is the second most common type of hospital-acquired infections. Pneumonia is an inflammatory condition of lungs and mainly affects the microscopic air sacs called alveoli. This is primarily caused by infection by bacteria or viruses and sometimes with other microorganisms. It can be mainly distinguished on how the infection was acquired.

Technavio’s analysts forecast the global hospital acquired pneumonia drugs market to grow at a CAGR of 2.22% during the period 2017-2021.

Covered in this report

The report covers the present scenario and the growth prospects of the global hospital acquired pneumonia drugs market for 2017-2021. To calculate the market size, the report presents a detailed picture of the market by way of study, synthesis, and summation of data from multiple sources.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA
Technavio's report, Global Hospital Acquired Pneumonia Drugs Market 2017-2021, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors
  • GlaxoSmithKline
  • Merck
  • Novartis
  • Pfizer
Other prominent vendors
  • Arsanis
  • AstraZeneca
  • Combioxin
  • Mylan
  • Shinogi
  • Sun Pharmaceutical Industries
  • Teva Pharmaceutical
  • The Medicines Company
  • Theravance Biopharma
Market driver
  • Unmet demand due to lack of available treatment for MDR microorganisms
  • For a full, detailed list, view our report
Market challenge
  • Growing cases of MDR microorganisms
  • For a full, detailed list, view our report
Market trend
  • Combination therapy for the treatment of HAP
  • For a full, detailed list, view our report
Key questions answered in this report
  • What will the market size be in 2021 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?


Press Release

Technavio Announces the Publication of its Research Report – Global Hospital Acquired Pneumonia Drugs Market 2017-2021
Technavio recognizes the following companies as the key players in the global hospital acquired pneumonia drugs market: GlaxoSmithKline, Merck, Novartis, and Pfizer.
Other Prominent Vendors in the market are: Arsanis, AstraZeneca, Combioxin, Mylan, Shinogi, Sun Pharmaceutical Industries, Teva Pharmaceutical, The Medicines Company, and Theravance Biopharma.
Commenting on the report, an analyst from Technavio’s team said: “One trend in the market is combination therapy for the treatment of HAP. Monotherapy is the common treatment given for nosocomial pneumonia. However, combination therapy has sometimes been found to be more appropriate and desirable treatment.”
According to the report, one driver in the market is unmet demand due to lack of available treatment for MDR microorganisms. Lack of proper treatment options available for the treatment of HAP because of MDR microorganisms is a major challenge for the healthcare providers. MDR microorganisms are those microorganisms that have developed antimicrobial drugs resistance. The resistance among various microorganisms to various antimicrobial drugs has emerged as a serious threat to public health across the globe.
Further, the report states that one challenge in the market is growing cases of MDR microorganisms. MDR microorganisms are the species of microorganisms that show resistance to multiple antimicrobial drugs. It may consist of bacteria, viruses, fungi, and many other parasites. MDR bacteria are the most threatening group of these microorganisms and have a huge impact on the public health. It is considered that approximately one-tenth of hospitalizations get complicated with healthcare-associated infections.

Companies Mentioned

GlaxoSmithKline, Merck, Novartis, Pfizer, Arsanis, AstraZeneca, Combioxin, Mylan, Shinogi, Sun Pharmaceutical Industries, Teva Pharmaceutical, The Medicines Company, and Theravance Biopharma.

  • Executive summary
  • Scope of the report
  • Research Methodology
  • Introduction
    • Key market highlights
  • Disease overview
    • Pneumonia
      • Table Classification of pneumonia
    • Types of pneumonia
      • Table Types of HAP
      • Table Symptoms and tests of HAP
  • Market landscape
    • Market overview
      • Table Global HAP drugs market snapshot
    • Market size and forecast
      • Table Global HAP drugs market 2016-2021 ($ millions)
      • Table Opportunity analysis of HAP drugs market
      • Table Five forces analysis
  • Pipeline analysis
    • Table Key pipeline molecules by vendors
    • Table Pipeline landscape
  • Market segmentation by drug class
    • Table Segmentation of global HAP drugs market by drug class
    • Table Global HAP drugs market share by drug class 2016 and 2021
    • Antibacterial drug
      • Table Uses and side effects of antibacterial drug
      • Table Global HAP antibacterial drugs market 2016-2021 ($ millions)
      • Table Causative microorganisms and empiric treatment
      • Table Brand mixtures for piperacillin-tazobactam
    • Antiviral drugs
      • Table Global HAP antiviral drugs market 2016-2021 ($ millions)
    • Others
      • Table Global HAP others drugs market 2016-2021 ($ millions)
  • Geographical segmentation
    • Table Segmentation of global HAP drugs market based on geography 2016 and 2021
    • Table Global HAP drugs market revenue by geography 2016-2021 ($ millions)
    • HAP drugs market in Americas
      • Table Market scenario in Americas
      • Table HAP drugs market in Americas 2016-2021 ($ millions)
    • HAP drugs market in EMEA
      • Table Market scenario in EMEA
      • Table HAP drugs market in the EMEA 2016-2021 ($ millions)
    • HAP drugs market in APAC
      • Table Market scenario in APAC
      • Table HAP drugs market in the APAC 2016-2021 ($ millions)
  • Decision framework
  • Drivers and challenges
    • Market drivers
      • Table Average percentage distribution of transplants by organ in US 1988-2016
    • Market challenges
  • Market trends
    • Combination therapy for the treatment of HAP
    • Growing preference for accurate diagnosis of disease
    • Rising R&D for effective treatment against superbugs/MDR microorganisms
  • Vendor landscape
    • Competitive landscape
      • Table Competitive structure analysis of global HAP drugs market 2016
  • Key vendor analysis
    • GlaxoSmithKline
      • Table GlaxoSmithKline: Key highlights
      • Table GlaxoSmithKline: Strength assessment
      • Table GlaxoSmithKline: Strategy assessment
      • Table GlaxoSmithKline: Opportunity assessment
    • Merck
      • Table Merck: Key highlights
      • Table Merck: Strength assessment
      • Table Merck: Strategy assessment
      • Table Merck: Opportunity assessment
    • Novartis
      • Table Novartis: Key highlights
      • Table Novartis: Strength assessment
      • Table Novartis: Strategy assessment
      • Table Novartis: Opportunity assessment
    • Pfizer
      • Table Pfizer: Key highlights
      • Table Pfizer: Strength assessment
      • Table Pfizer: Strategy assessment
      • Table Pfizer: Opportunity assessment
    • Other prominent vendors
  • Appendix
    • List of abbreviations
  • Explore Technavio

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook

Share this report